Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients With Diabetes
Open Access
- 20 April 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (12), 1476-1481
- https://doi.org/10.1200/jco.2006.07.2777
Abstract
Purpose: Peroxisome proliferator-activated receptor gamma (PPARγ) mediates cell cycle arrest and adipocyte differentiation; has tumor suppressor activity in liposarcoma, lung, and prostate cancers; and suppresses colonic polyp formation in adenomatous polyposis coli (APC)min/+ mice. To assess the influence of thiazolidinediones (TZDs), which are PPARγ ligands used to treat diabetes mellitus, a retrospective analysis of a database from 10 Veteran Affairs medical centers was conducted. Patients and Methods: Data on male patients 40 years and older diagnosed to have diabetes mellitus between 1997 and 2003 were obtained from the Veterans Integrated Services Network 16 (VISN 16) data warehouse. Subsequent diagnoses of colorectal, lung, and prostate cancer and use of TZD, other antidiabetic agents, and insulin were identified. Cox regression with time-dependent covariates was used to estimate the association between TZD use and cancer risk. Relative risks were adjusted for confounders (age, race/ethnicity, body mass index, use of insulin, and other oral antidiabetic agents). Results: Of 87,678 individuals, 1,137 had colorectal cancer, 3,246 had prostate cancer, and 1,371 had lung cancer. We observed a 33% reduction in lung cancer risk among TZD users compared with nonusers after adjusting for confounder interactions (relative risk, 0.67; 95% CI, 0.51 to 0.87). The risk reduction for colorectal and prostate cancers did not reach statistical significance. Conclusion: TZD use was associated with reduced risk of lung cancer. Further studies are warranted to confirm our findings.Keywords
This publication has 24 references indexed in Scilit:
- Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPAR?) signaling in prostate cancerJournal of Cellular Biochemistry, 2004
- Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancerOncogene, 2004
- Peroxisome-proliferator-activated receptors and cancers: complex storiesNature Reviews Cancer, 2004
- PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesisJCI Insight, 2002
- Understanding the cancer biology universe: enigmas, context and future prospects.Cancer Biology & Therapy, 2002
- Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesisJournal of Molecular Endocrinology, 2001
- Inhibition of Human Lung Cancer Cell Growth by the Peroxisome Proliferator-Activated Receptor-γ Agonists through Induction of ApoptosisBiochemical and Biophysical Research Communications, 2000
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*Endocrine Reviews, 1999
- Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer CellsJapanese Journal of Cancer Research, 1999
- Activators of the nuclear receptor PPARγ enhance colon polyp formationNature Medicine, 1998